Wolfe Research last night initiated coverage of Beta Bionics (BBNX) with an Outperform rating and $20 price target Insulin pumps are a double-digit growth category and Beta from a low base is taking share, the analyst tells investors in a research note. The firm says the company’s revenue in the U.S. pump market has grown low-to-mid-teens over the last three years. Wolfe believes Beta Bionics’ “differentiated” user experience and pharmacy preferred access strategy support continuation of faster than category-growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics initiated with a Neutral at Goldman Sachs
- Beta Bionics initiated with an Outperform at Wolfe Research
- Positive Developments and Strategic Advancements Drive Buy Rating for Beta Bionics, Inc.
- Beta Bionics Q1 2025 Earnings: Strong Growth and Optimism
- Strong Performance and Growth Potential: Buy Rating for Beta Bionics, Inc.